KEYTRUDA as Monotherapy Reduced Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent ...
Updated efficacy data in 34 evaluable patients with a chemotherapy-free regimen; randomized Part C will add BI-1808 to the ...
Moderna is rated a Hold, citing valuation concerns, lack of definitive long-term efficacy data, and significant execution and ...
Intismeran plus KEYTRUDA significantly reduced the risk of recurrence or death by 42% (HR=0.58 [95% CI, 0.45–0.75]; two-sided p<0.001) compared to KEYTRUDA alone for patients with completely resected ...
The FDA grants traditional approval to Keytruda and Keytruda Qlex for TMB-H solid tumors, updating the threshold to at least ...
The FDA converted the accelerated approval of pembrolizumab in TMB-high solid tumors to traditional approval, redefining ...
The approval covers IV and subcutaneous pembrolizumab and raises the TMB-H threshold from 10 to 13 mutations/megabase.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Commission (EC) has approved KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results